Journal
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
Volume 7, Issue 4, Pages 208-214Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040622316653306
Keywords
Crohn's disease; interleukin 12; 23p40 inhibitor; ustekinumab
Categories
Ask authors/readers for more resources
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available